患有中风后的患者的抗发作药物:一个生存分析研究
Ippazio Cosimo Antonazzo1,2,3,4, Carla Fornari1, Gabriele Buongarzone1
1Research Centre on Public Health (CESP), University of Milano-Bicocca, Monza, Italy.
Epilepsia
|November 7, 2025
概括
在中风后 (PSE) 患者中使用抗发作药物 (ASM) 与死亡风险显著降低有关. 这项研究表明,ASM可能会改善这一高风险群体的生存率.
科学领域:
- 神经学 神经学
- 流行病学 流行病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 脑卒中后 (PSE) 是一个重大的临床挑战.
- 抗发作药物 (ASM) 对PSE患者生存的影响仍未得到充分研究.
- 关于ASM使用与PSE死亡率之间的关联的证据有限.
研究的目的:
- 评估抗发作药物 (ASM) 使用与被诊断患有中风后 (PSE) 的患者全因死亡率之间的关联.
- 为了确定ASM治疗是否会影响PSE患者的生存率.
主要方法:
- 一项回顾性队列研究利用了意大利伯加莫 (2014-2017) 的医疗保健行政数据.
- 包括中风和随后发作的患者,并从诊断 (索引日期) 开始进行随访.
- ASM暴露被定义为在索引日期后30天内给予;用于死亡率分析,使用了Cox比例危险模型.
主要成果:
- 该研究包括145名患者:107名ASM使用者和38名非使用者.
- 对治疗意图的分析显示,ASM使用与全因死亡率降低有关 (aHR:0.56;95%CI:0.33-0.95).
- 时间依赖的分析产生了一致的结果,表明ASM用户的死亡风险较低 (aHR:0.39;95%CI:0.23-0.65).
结论:
- 在中风后患者中使用抗发作药物 (ASM) 与所有死因死亡风险的降低显著相关.
- 这些发现表明,ASM治疗可能会在高风险的PSE人群中提供生存益处.
- 需要进一步的研究来证实ASM在PSE中的增强生存效应.
相关概念视频
Epilepsy and Seizures: Overview
1.1K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.1K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
802
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
802
Seizures: Classification
1.3K
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
1.3K
Antiepileptic Drugs: Potassium Channel Activators
616
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
616
Antiepileptic Drugs: Sodium Channel Blockers
1.6K
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
1.6K
Antiepileptic Drugs: Calcium Channel Blockers
1.1K
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
1.1K


